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Background and Objectives: Vitamin D plays an important role in bone and muscle function, and cell prolifera-
tion. The impact of chemotherapy and associated behavioural changes such as fatigue and sun avoidance on vit-
amin D (25(OH) D) is unknown. This study aims to evaluate variations in serum vitamin D during chemotherapy 
and the predictive value of latitude, season and pre-existing vitamin D deficiency. Methods and Study Design: 
A 12-week prospective cohort study was conducted in chemotherapy-naïve patients in two Australian locations 
with different sun exposure. Vitamin D deficiency was defined as ≤25 nmol/L and insufficiency 26-50 nmol/L 
25(OH) D. Demographics, chemotherapy regimen, nutritional status, sun exposure, geographic location, and sea-
son were collected at baseline, 6 and 12 weeks after commencing chemotherapy. Results: Eighty-five patients 
(μ55.3±13.4 years of age; 49% female) were recruited, 96% Caucasian. Fifty-four patients were treated with cura-
tive intent (mostly for breast [n=29] or colorectal [n=12] cancers). At baseline, 10 patients were vitamin D defi-
cient and 33 were insufficient. Mean serum 25(OH) D (nmol/L) was higher at latitude -27.5o (Brisbane) than lati-
tude -34.9o (Adelaide) (μ61.9±22.1 vs. μ42.2±19.2, p<0.001) and varied according to season (spring: μ46.9±20.3, 
summer: μ50.8±18.2, autumn: μ76.4±25.2, winter: μ36.5±15.7, p<0.001). Serum 25(OH) D decreased with 
chemotherapy (baseline: μ49.2±22.3, 6-weeks: μ40.9±19.0, 12-weeks: μ45.9±19.7, p=0.05), with a significant 
and more rapid decline in winter and autumn (p=0.03). Conclusions: Chemotherapy is associated with a decrease 
in serum vitamin D, particularly during winter and autumn. Investigations into the underlying mechanism and as-
sociated potential outcomes with this decrease requires further investigation. 
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INTRODUCTION 
Vitamin D is important for bone health, with vitamin D 
deficiency leading to osteopenia or osteoporosis in adults. 
The prevalence of vitamin D (25(OH) D) deficiency var-
ies from 5% in USA, 11% in the South Pacific, 17% in 
South East Asia and, 27% in Europe.1 Even in regions of 
high ultraviolet radiation (UVR) such as Australia, up to 
40% of adults have low vitamin D status.2 The risk fac-
tors for deficiency include age, BMI, ambient UVR (e.g. 
geographic location) and UVR exposure behaviours (e.g. 
clothing and sunscreen use).3,4 
In recent years, research focus has shifted from the  
 
 
classical bone and muscle functions of vitamin D to its 
growth-regulating actions such as the regulation of cell 
proliferation and differentiation, immune-modulator ac-  
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tion, and potential therapeutic roles in disease manage-
ment. Emerging research suggests the potential role of 
vitamin D in cancer prevention,5 prevention of cancer 
progression6-9 and reduction in cancer-associated compli-
cations such as arthralgia, muscle weakness, and bisphos-
phonate toxicity.10-12 In 2017, a meta-analysis revealed 
that higher levels of circulating 25(OH) D had a 25% 
lower risk of mortality in breast cancer patients 
(HR=0.75, 95% CI=0.56 to 0.95; n=9 studies; n=7,262 
participants).13  
Cancer patients have a higher prevalence of vitamin D 
deficiency than the general population, where up to 67% 
have insufficiency.14 In an electronic chart review of over 
39,000 adults with solid tumours in the USA, it was con-
cluded that vitamin D deficiency was common, and para-
doxically those at greatest risk were the least likely to be 
tested.15 This indicates that cancer patients are an ‘at risk’ 
group and that there may be additional risk factors for 
low levels of vitamin D. Two retrospective studies in the 
USA and France found that those undergoing chemother-
apy or with a history of chemotherapy treatment in the 
past three months were at greater risk of having vitamin 
D deficiency.16,17 Although these studies adjusted for diet 
and UVR exposure at baseline they did not assess the 
influence of the season during treatment on the changes in  
vitamin D status.  
The actual impact of chemotherapy and associated life-
style behaviours on serum 25(OH) D concentration is 
unknown since vitamin D status is not routinely assessed 
before or throughout chemotherapy.  Additionally, it is 
possible that behavioural changes associated with cancer 
treatments such as fatigue, decreased time spent outdoors, 
dietary changes and sun avoidance (incidental and medi-
cally advised) may be predictive of low vitamin D status 
in this group. To address this gap in the current body of 
evidence, this study aimed to evaluate variations in serum 
25(OH) D during treatment in chemotherapy-naïve medi-
cal oncology patients in two geographically distinct Aus-
tralian settings with different levels of sun exposure. The 
secondary aim was to determine potential predictors of 
change including age, nutritional status, BMI, gender, 
location of residence, season and pre-existing vitamin D 
deficiency and insufficiency on vitamin D levels follow-
ing chemotherapy treatment. 
 
METHODS 
This study was a 12-week observational, prospective co-
hort study of chemotherapy-naïve (i.e. no prior chemo-
therapy) patients commencing chemotherapy treatment in 
two Australian sites located at different latitudes (Ade-
laide, South Australia: -34.9o; Brisbane, Queensland; -
27.5o). A consecutive sample of adult medical oncology 
patients with a histologically confirmed cancer, which 
were chemotherapy-naïve and planning to commence 
chemotherapy within 2 weeks was offered study entry 
and written informed consent was obtained. This study 
was approved by the Princess Alexandra Hospital Human 
R e s e a r c h  E t h i c s  C o m m i t t e e  ( H R E C ; 
U C H R E C / 1 0 / Q P A H / 
22), Southern Adelaide Clinical HREC (126-10), and the 
University of Queensland (UQ2010000903). 
At baseline (commencement of chemotherapy), demo-
graphic and clinical data including age, gender, measured 
height and weight, ethnicity, primary site, treatment intent 
and planned chemotherapy treatment were recorded. A 
dietitian trained to assess nutritional risk and status ad-
ministered the validated Patient-Generated Subjective 
Global Assessment (PG-SGA) tool.18 The PG-SGA, sun 
exposure in the previous 7-days (low <2 hours; moderate 
2-12 hours; high >12 hours), and 7-day intake of vitamin 
D-rich foods (e.g. oily fish and vitamin D fortified milk) 
were collected at baseline, 6 and 12 weeks after com-
mencing chemotherapy. Data pertaining to chemotherapy 
regimen, medication and supplement use were collected 
at baseline and changes were captured during follow-up  
interviews. 
Non-fasting blood samples were taken at baseline, 6 
and 12 weeks and collected at the same time as chemo-
therapy treatment blood draws whenever possible. Serum 
was separated by centrifugation within 4 hours of collec-
tion and stored at -80oC until analysis. Serum was batch-
analysed for 25(OH) D concentrations at the AusSun Re-
search Laboratory at the Queensland University of Tech-
nology using Diasorin® liaison semi-automated chemo-
luminescence immunoassay (DiaSorin). Vitamin D defi-
ciency and insufficiency was defined as <25 nmol/L (<10 
ng/mL) and 25-50 nmol/L (10-20ng/mL) 25(OH) D, re-
spectively.19 The laboratory technician performing the 
assay was blinded to all personal and medical characteris-
tics of the patients.  
 
Statistical analysis  
The STATA statistical software package was used for all 
analysis (version 12.0, StataCorp, Texas, USA). Baseline 
characteristics of the subjects were described using mean 
± SD for normally distributed continuous variables and 
median (range) for non-normally distributed continuous 
variables. Population-averaged effects were obtained us-
ing generalised estimating equations with a Gaussian dis-
tribution and identity link to estimate the association be-
tween patient characteristics and serum 25(OH) D. These 
models use all available data over the follow up, and take 
into account correlated repeated measures in the same 
individual. Patient characteristics that were assessed in 
univariate analysis were age, gender, BMI, sun exposure, 
intake of vitamin D rich foods, nutritional status, state of 
residency (by latitude), treatment period (0, 6 or 12 weeks 
since start of chemotherapy) and whether or not the pa-
tient was currently receiving treatment (yes/no). Variables 
that were significant at p<0.1 in univariate analysis were 
considered for inclusion in a multivariate model. Age, 
gender, BMI and chemotherapy status were included in 
the multivariate model a priori. Interaction terms assessed 
for inclusion in the multivariate model were those be-
tween treatment period and all other covariates. We de-
fined statistical significance as those effects with p<0.05 
in two-tailed tests. 
 
RESULTS 
A total of 85 participants were recruited (n=33 Queens-
land; n=52 South Australia); however, only 81 were in-
cluded in the analysis as four participants did not attend 
the baseline vitamin D blood test (Figure 1). Following 
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baseline, 14 participants were lost to follow-up. Table 1 
describes the demographics and clinical characteristics; 
participants were similar across the two states (p>0.05; 
data not shown).   
 
Change in 25(OH) D concentrations  
The 25(OH) D serum concentration at baseline was 
μ49.2±22.3 nmol/L. Ten (12%) patients were vitamin D 
deficient at baseline and a further 33 (41%) insufficient. 
Queensland patients had significantly higher serum 
25(OH) D concentrations compared with South Australia 
at baseline (μ61.9±22.1 versus μ42.2±19.2 nmol/L, 
p<0.001) and 6-weeks (μ49.3±21.4 versus μ37.5±17.1 
nmol/L, p=0.02) but not 12-weeks (μ51.9±19.4 versus 
μ42.8±19.5 nmol/L, p=0.07). Seventy-six (89%) patients 
were still receiving chemotherapy treatment at 6-weeks 
follow-up and 55 (65%) patients at 12-weeks follow-up. 
 
Predictors of change 
In univariate analysis, treatment period (p=0.004), season 
(p<0.001), state (latitude) (p<0.001), treatment period x 
season (p<0.001) and treatment period x state (latitude) 
(p=0.03) were significant predictors of serum 25(OH) D. 
These variables as well as nutritional status (PG-SGA) 
score (p=0.08) and high fish intake (p=0.10) were consid-
ered for inclusion in the multivariate model. In multivari-
ate analysis, adjusted for age, gender, BMI and chemo-
therapy status, serum 25(OH) D concentrations were 
higher in Queensland compared to South Australia 
(μ61.9±22.1 versus μ42.2±19.2 nmol/L, p<0.001) and 
varied significantly according to season (spring: 
μ46.9±20.3, summer: μ50.8±18.2, autumn: μ76.4±25.2, 
and winter: μ36.5±15.7 nmol/L, p<0.001). There was a 
trend towards a treatment period effect with an overall 
decline in serum 25(OH) D concentrations at 6 and 12 
weeks compared to baseline (baseline: μ49.2±22.3, 6-
weeks μ40.9±19.0, 12-weeks μ45.9±19.7 nmol/L, 
p=0.05). Decline also varied according to season (p=0.03 
for treatment period x season interaction) with declines in 
serum 25(OH) D across the 12-weeks in winter (p=0.002 
at 12-weeks) and autumn (p=0.004 at 12-weeks), but de-
clines only in the first 6 weeks for summer (p=0.04 at 6-
weeks and p=0.41 at 12-weeks) and no declines in spring 
(p=0.05 at 6-weeks and p=0.86 at 12-weeks). Figure 2 
shows the averaged declines for Spring/Summer and 
Winter/Autumn (p<0.001 for interaction) Compared to 
baseline values, Vitamin D declined by 11.7±5.4 
(p=0.003) more in Autumn/Winter compared to 
 
 
Figure 1. Study design and patient flow 
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Spring/Summer and by 25.7±5.0 (p<0.001) in Au-
tumn/Winter compared to Spring/Summer. 
    When consumption of vitamin D enriched milk and/or 
high fish intake were considered as a single variable, 
there was a tendency towards reduced odds of 25(OH) D 
insufficiency with consumption of either item (OR: 0.463 
[95%CI: 0.209-1.030] p=0.059). There were no signifi-
cant independent associations between 25(OH) D and 
age, gender, BMI, nutritional status, or vitamin D en-
riched milk or high fish intake as separate variables. 
There were no additional independent effect of current 
chemotherapy treatment (receiving/not-receiving chemo-
therapy) beyond that ascribed to the treatment period ef-
fect (i.e. the time since commencing chemotherapy). 
 
 
DISCUSSION 
This is the first Australian prospective study examining 
vitamin D changes from the commencement of chemo-
therapy; and is also the first Australian study to account 
for factors known to influence 25(OH) D concentrations 
in this population. This study shows that vitamin D defi-
ciency and insufficiency is common at baseline in Aus-
tralian cancer patients, and confirms that chemotherapy 
was independently associated with a significant decrease 
in serum 25(OH) D concentration, particularly when 
treatment was undertaken during autumn and winter. The 
decline was also significantly influenced by the state of 
residence (Queensland vs South Australia), highlighting 
the importance of ambient sun availability. This finding is 
in agreement with previous studies (Unknown site, 
France; New York, USA; Brisbane, Australia; 25 sites 
across the Netherlands);16,17,20,21 however, this study is the 
first to measure 25(OH) D in chemotherapy patients pro-
spectively in Australia.  
The decline in 25(OH) D concentrations was season-
dependent; which suggests changes in ambient UVR may 
have influenced serum 25(OH) D concentrations. This 
hypothesis is further strengthened by the observation that 
the chemotherapy-associated decline in 25(OH) D con-
centrations was more pronounced in winter and autumn. 
The recovery of 25(OH) D observed at 12 weeks was 
only seen in the summer and spring months. In addition, 
seasonal clothing and dietary habits, as well as time out-
doors, may compound the effects of lower ambient UVR 
in the cooler months. Intentional and unintentional sun 
avoidance as a consequence of reduced outdoor physical 
activity22 or photosensitisers such as fluorouracil23 would 
also reduce skin vitamin D production. Interestingly, pa-
tient-reported sun exposure in our study was not associat-
ed with 25(OH) D concentrations. This may be explained 
by the lag time between the reported period of the sun 
exposure (past week) and the 2-3-week half-life of serum 
25(OH) D, suggesting sun exposure needs to be measured 
over a longer period of time. Researchers should also 
consider the assessment of clothing and sunscreen habits 
in the evaluation of sun exposure and vitamin D in chem-
otherapy patients.  
Dietary changes at the time of chemotherapy impacting 
vitamin D intake and production may also explain the 
observed serum 25(OH) D decrease. Patients undergoing 
chemotherapy have been reported to alter their dietary 
habits as a consequence of treatment-related symptoms, 
either through reduced or modified intake to minimise the 
impact of these symptoms. Interestingly, combined con-
sumption of vitamin D rich oily fish and vitamin D forti-
fied milk had a trend towards decreased risk of vitamin D 
insufficiency, suggesting some role of the diet in manag-
ing risk of vitamin D deficiency in chemotherapy.  
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Figure 2. Predicted marginal mean levels (95% CI) of serum 25(OH)D by time since commencing chemotherapy and seasonal periods in 
85 chemotherapy-naïve patients 
 
 
 
 
 
 
Table 1. Demographic and clinical characteristics of study participants 
 
Characteristic Result 
Age (years), mean±SD 55.3±13.4 
Sex, n (%)  
 Male 36 (42.3) 
 Female 49 (57.7) 
Ethnicity, n (%)  
 Caucasian 81 (95.3) 
 Other 4 (4.7) 
Weight (kg), median (range) 75 (50-151) 
BMI (kg/m2), n (%)  
 <18.5 (underweight) 2 (2.35) 
 18.5-24.9 (normal range) 27 (31.8) 
 25-29.9 (overweight) 28 (32.9) 
 ≥30  (obese) 28 (32.9) 
Nutrition assessment, n (%)  
 PG-SGA rating A (well nourished) 67 (78.8) 
 PG-SGA rating B (moderately malnourished or suspected malnutrition) 18 (21.2) 
 PG-SGA rating C (severely malnourished) 0 (0.0) 
Primary site, n (%)  
 Breast 29 (34) 
 Colorectal 12 (14) 
 Other 10 (11) 
 Lymphoma 9 (11) 
 Leukaemia 7 (8) 
 Lung 7 (8) 
 Ovarian 5 (6) 
 Testis 3 (4) 
 Unknown primary 3 (4) 
 
BMI: body mass index; PG-SGA: patient-generated subjective global assessment. 
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The association of chemotherapy and 25(OH) D con-
centrations may further indicate metabolic mechanisms 
for vitamin D change. Vitamin D may be converted to 
inactive metabolites by upregulation of the cytochrome 
P450 enzymes as a response to chemotherapy. It has also 
recently been shown that vitamin D-binding protein 
(DBP) is associated with 25(OH) D concentrations.24 
Powe and colleagues24 reported a higher prevalence of 
vitamin D deficiency and a lower concentration of DBP 
in Black Americans. In patients undergoing chemothera-
py, there is a shift in the metabolism of albumin, with 
much lower levels of this protein in the serum, usually 
attributed to hepatotoxicity and the acute phase response. 
Although not measured here, it is plausible that reduced 
liver function also affects the concentrations of DBP and 
thus 25(OH) D. It would be interesting to explore the as-
sociation between chemotherapy and DBP and vitamin D 
levels in future studies and relate these to cancer out- 
comes. 
While our findings add to the body of evidence that 
suggests that vitamin D deficiency and insufficiency is 
common among cancer patients, the evidence to support 
routine supplementation with vitamin D is insufficient. 
Although vitamin D (combined with calcium) supplemen-
tation in post-menopausal women was found not to pre-
vent all-type cancer incidence,25 a recent systematic re-
view and meta-analysis found good evidence for a causal 
link between vitamin D status and genotype with cancer 
outcome.13 Interventional research is needed to establish 
the optimal supplementation dose, treatment period, safe-
ty and efficacy of vitamin D supplementation in chemo-
therapy patients on both short and long-term patient out-
comes. 
The major limitation of this study was that the follow-
up period may have been too short for long-term changes 
and/or recovery of 25(OH) D concentrations to be ob-
served. The study was also limited in that cancer-related 
outcomes such as bone turnover markers and muscle 
function were not addressed. In addition, the diversity of 
chemotherapy treatments in this sample would not be 
adequately powered to detect differences between chemo-
therapy regimens, particularly those that are photosensi-
tising. Future studies should utilise measures of body 
composition such as DXA or bioelectrical impedance 
analyses and ultraviolet radiation dosimeter badges in 
conjunction with sun exposure behaviours to measure  
UVR exposure.  
 
Conclusion 
Chemotherapy is associated with a decrease in serum 
25(OH) D for chemotherapy-naïve patients during treat-
ment and this is most pronounced in autumn and winter 
and at lower latitudes. Further research is needed to de-
termine the underlying mechanism by which chemothera-
py may be impacting on 25(OH) D concentrations, the 
patient-related outcomes associated with this decrease, 
and interventional approaches for preventing/correcting 
vitamin D decreases during chemotherapy. 
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